Biotech stock Halozyme Therapeutics is climbing back in constructive form from a severe drop in November. Shares got a boost after the drug-delivery developer reiterated its 2024 forecast and raised ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ:BIOA) pursuant and/or traceable to BioAge's registration statement for the initial public ...

Hims stock surged into a profit-taking zone Friday after facing backlash over its provocative Super Bowl ad that criticized the makers of approved weight-loss drugs. Please watch the video at ...

Scams involving celebrities or other famous people aren't really new - and are simply a modern take on the "Spanish Prisoner" or "Nigerian Prince" schemes ...

Eli Lilly ( LLY 3.89%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Analysts are bullish on the maker of weight-loss drugs Zepbound and Mounjaro, with 10 of the 11 analysts who follow the company and are tracked by Visible Alpha rating Eli Lilly stock as a "buy ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news ...

Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...

This would not only drive sales growth but also reinforce Eli Lilly's position as an innovator in the metabolic disease space, potentially leading to increased investor confidence and stock ...